Skip to main content
Top
Published in: Documenta Ophthalmologica 2/2010

01-10-2010 | Case report

Macular vitelliform lesion in desferrioxamine-related retinopathy

Authors: Mohamed A. Genead, Gerald A. Fishman, Anastasios Anastasakis, Martin Lindeman

Published in: Documenta Ophthalmologica | Issue 2/2010

Login to get access

Abstract

To report a case of a macular vitelliform lesion associated with desferrioxamine treatment. Ocular, electrophysiological, psychophysical, perimetric, fluorescein angiographic, fundus autofluorescence, and spectral-domain OCT examinations were obtained on a 45-year-old Caucasian woman with thalassemia major treated with blood transfusions and desferrioxamine. The patient was observed to have a vitelliform macular lesion in the right eye with a hypopigmented macular lesion and retinal pigment mottling in the left. At the most recent follow-up visit, best-corrected visual acuity was 20/70 in the right eye and 20/25 in left. Full-field electroretinogram (ERG) testing showed normal cone and rod responses. Mild localized elevations of rod psychophysical thresholds were found. A vitelliform macular lesion can develop in patients treated with desferrioxamine. Some such patients may not show diffuse photoreceptor cell functional loss as determined by electrophysiological testing.
Literature
1.
2.
go back to reference Lakhanpal V, Schocket SS, Jiji R (1984) Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 91:443–451PubMed Lakhanpal V, Schocket SS, Jiji R (1984) Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 91:443–451PubMed
3.
go back to reference Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER (1983) Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 2:181–184CrossRefPubMed Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER (1983) Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 2:181–184CrossRefPubMed
4.
go back to reference Orton RB, de Veber LL, Sulh HM (1985) Ocular and auditory toxicity of long-term, high-dose subcutaneous Deferoxamine therapy. Can J Ophthalmol 20:153–156PubMed Orton RB, de Veber LL, Sulh HM (1985) Ocular and auditory toxicity of long-term, high-dose subcutaneous Deferoxamine therapy. Can J Ophthalmol 20:153–156PubMed
5.
go back to reference Cases A, Kelly J, Sabater F, Torras A, Griño MC, Lopez-Pedret J, Revert L (1990) Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron 56:19–23CrossRefPubMed Cases A, Kelly J, Sabater F, Torras A, Griño MC, Lopez-Pedret J, Revert L (1990) Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron 56:19–23CrossRefPubMed
6.
go back to reference Mehta AM, Engstrom RE Jr, Kreiger AE (1994) Deferoxamine associated retinopathy after subcutaneous injection [letter]. Am J Ophthalmol 118:260–262PubMed Mehta AM, Engstrom RE Jr, Kreiger AE (1994) Deferoxamine associated retinopathy after subcutaneous injection [letter]. Am J Ophthalmol 118:260–262PubMed
7.
go back to reference De Virgiliis S, Congia M, Turco MP, Frau F, Dessi C, Argiolu F, Sorcinelli R, Sitzia A, Cao A (1988) Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child 63:250–255CrossRefPubMed De Virgiliis S, Congia M, Turco MP, Frau F, Dessi C, Argiolu F, Sorcinelli R, Sitzia A, Cao A (1988) Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child 63:250–255CrossRefPubMed
8.
go back to reference Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E (1990) Vision and hearing during deferoxamine therapy. J Pediatr 117:326–330CrossRefPubMed Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E (1990) Vision and hearing during deferoxamine therapy. J Pediatr 117:326–330CrossRefPubMed
9.
go back to reference Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S (2002) The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109:164–171CrossRefPubMed Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S (2002) The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109:164–171CrossRefPubMed
10.
go back to reference Bansal V, Elgarbly I, Ghanchi FD, Atkinson PL (2003) Bull’s eye maculopathy with deferoxamine. Eur J Haematol 70(6):420–421CrossRefPubMed Bansal V, Elgarbly I, Ghanchi FD, Atkinson PL (2003) Bull’s eye maculopathy with deferoxamine. Eur J Haematol 70(6):420–421CrossRefPubMed
11.
go back to reference Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M (2009) ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 118:69–77CrossRefPubMed Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M (2009) ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 118:69–77CrossRefPubMed
12.
go back to reference Pall H, Blake DR, Winyard P, Lunec J, Williams A, Good PA, Kritzinger EE, Cornish A, Hider RC (1989) Ocular toxicity of desferrioxamine-an example of copper promoted auto-oxidative damage? Br J Ophthalmol 73:42–47CrossRefPubMed Pall H, Blake DR, Winyard P, Lunec J, Williams A, Good PA, Kritzinger EE, Cornish A, Hider RC (1989) Ocular toxicity of desferrioxamine-an example of copper promoted auto-oxidative damage? Br J Ophthalmol 73:42–47CrossRefPubMed
13.
go back to reference Chaston TB, Richardson DR (2003) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol 73:200–210CrossRefPubMed Chaston TB, Richardson DR (2003) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol 73:200–210CrossRefPubMed
14.
go back to reference Gonzales CR, Lin AP, Engstrom RE, Kreiger AE (2004) Bilateral vitelliform maculopathy and deferoxamine toxicity. Retina 24(3):464–467CrossRefPubMed Gonzales CR, Lin AP, Engstrom RE, Kreiger AE (2004) Bilateral vitelliform maculopathy and deferoxamine toxicity. Retina 24(3):464–467CrossRefPubMed
15.
go back to reference Arden GB, Wonke B, Kennedy C, Huehns ER (1984) Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 68(12):873–877CrossRefPubMed Arden GB, Wonke B, Kennedy C, Huehns ER (1984) Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 68(12):873–877CrossRefPubMed
16.
go back to reference Jiang C, Hansen RM, Gee BE, Kurth SS, Fulton AB (1999) Rod and rod mediated function in patients with beta-thalassemia major. Doc Ophthalmol 96(4):333–345CrossRef Jiang C, Hansen RM, Gee BE, Kurth SS, Fulton AB (1999) Rod and rod mediated function in patients with beta-thalassemia major. Doc Ophthalmol 96(4):333–345CrossRef
17.
go back to reference Roulez F (2007) Retinal pigment epithelium-desferal. Bull Soc Belge Ophtalmol (304):59–66 Roulez F (2007) Retinal pigment epithelium-desferal. Bull Soc Belge Ophtalmol (304):59–66
18.
go back to reference Bene C, Manzler A, Bene D, Kranias G (1989) Irreversible ocular toxicity from single “challenge” dose of deferoxamine. Clin Nephrol 31(1):45–48PubMed Bene C, Manzler A, Bene D, Kranias G (1989) Irreversible ocular toxicity from single “challenge” dose of deferoxamine. Clin Nephrol 31(1):45–48PubMed
Metadata
Title
Macular vitelliform lesion in desferrioxamine-related retinopathy
Authors
Mohamed A. Genead
Gerald A. Fishman
Anastasios Anastasakis
Martin Lindeman
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Documenta Ophthalmologica / Issue 2/2010
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-010-9236-z

Other articles of this Issue 2/2010

Documenta Ophthalmologica 2/2010 Go to the issue